Teduglutide treatment in a short bowel syndrome

• Marta Bellver Albertos ; Mónica Montero Hernández ^[1] ; Álvaro Medina Guerrero ^[1] ; Rafael Gil Borras ^[1]
  1. [1] Hospital Arnau de Vilanova

     Hospital Arnau de Vilanova

     Valencia, España

     
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 20, Nº. 5, 2018, págs. 250-256
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Teduglutide, was approved for adult patients with short bowel syndrome with intestinal failure. It might restore intestinal structural and functional integrity. Our patient endured a surgical resection ought to superior mesenteric artery thrombosis. In June 2016 started treatment with teduglutide. It has decreased the daily parenteral nutrition and fluids requirements in volume and time. It has reduced in a 53% (from baseline 1,590 ml to 840 ml) the parenteral nutrition volume and a 38% (from baseline 2,000 ml to 1,250 ml) the fluids support. It has also reduced the time of parenteral support in seven hours. The patient increased his weight and quality of life during the treatment